Novo Nordisk-Metsera deal may raise HSR issues, US FTC says
MLex Summary: Novo Nordisk’s proposed acquisition of Metsera may raise serious issues without filing under the Hart-Scott-Rodino Act, the US Federal Trade Commission told Novo Nordisk in a letter. The FTC...To view the full article, register now.
Already a subscriber? Click here to view full article